Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)

被引：0
|
作者：
Kate McKeage
Barbara Romanowski
机构：
[1] Adis,Division of Infectious Diseases
[2] a Wolters Kluwer Business,undefined
[3] University of Alberta,undefined
来源：
BioDrugs | 2011年 / 25卷
关键词：
Cervical Intraepithelial Neoplasia; Sexual Debut; Cervarix; Premalignant Cervical Lesion; Aluminum Hydroxyphosphate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The AS04-adjuvanted human papillomavirus (HPV) 16/18 vaccine (Cervarix®) is a noninfectious recombinant vaccine produced using purified virus-like particles (VLPs) that induce a strong immunogenic response eliciting high levels of anti-L1 VLP antibodies that persist at levels markedly greater than those observed with natural infection. The vaccine adjuvant (AS04) is composed of monophosphoryl-lipid A, which enhances cellular and humoral immune response, adsorbed to aluminum hydroxide. The vaccine is indicated for the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types in females aged ≥10 years.
引用
收藏
页码：265 / 269
页数：4
相关论文
共 50 条
  • [21] Correlation between levels of human papillomavirus (HPV)-16 and-18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine
    Schwarz, Tino F.
    Kocken, Marielle
    Petaja, Tiina
    Einstein, Mark H.
    Spaczynski, Marek
    Louwers, Jacqueline A.
    Pedersen, Court
    Levin, Myron
    Zahaf, Toufik
    Poncelet, Sylviane
    Hardt, Karin
    Descamps, Dominique
    Dubin, Gary
    [J]. HUMAN VACCINES, 2010, 6 (12): : 1054 - 1061
  • [22] Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
    Kim, Young-Jae
    Kim, Kyung-Tai
    Kim, Jae-Hoon
    Cha, Soon-Do
    Kim, Jae Weon
    Bae, Duk-Soo
    Nam, Joo-Hyun
    Ahn, Woong-Shick
    Choi, Ho-Sun
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (08) : 1197 - 1204
  • [23] Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study
    Tota, Joseph E.
    Struyf, Frank
    Hildesheim, Allan
    Gonzalez, Paula
    Ryser, Martin
    Herrero, Rolando
    Schussler, John
    Karkada, Naveen
    Rodriguez, Ana Cecilia
    Folschweiller, Nicolas
    Porras, Carolina
    Schiffman, Mark
    Schiller, John T.
    Quint, Wim
    Kreimer, Aimee R.
    Lehtinen, Matti
    Wheeler, Cosette M.
    Sampson, Joshua N.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (09): : 1576 - 1581
  • [24] Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9–14 Years in the EU
    Katherine A. Lyseng-Williamson
    [J]. Pediatric Drugs, 2014, 16 : 247 - 253
  • [25] Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women
    Bhatla, Neerja
    Suri, Vanita
    Basu, Partha
    Shastri, Surendra
    Datta, Sanjoy K.
    Bi, Dan
    Descamps, Dominique J.
    Bock, Hans L.
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2010, 36 (01) : 123 - 132
  • [26] Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
    Szarewski, A.
    Poppe, W. A. J.
    Skinner, S. R.
    Wheeler, C. M.
    Paavonen, J.
    Naud, P.
    Salmeron, J.
    Chow, S-N.
    Apter, D.
    Kitchener, H.
    Castellsague, X.
    Teixeira, J. C.
    Hedrick, J.
    Jaisamrarn, U.
    Limson, G.
    Garland, S.
    Romanowski, B.
    Aoki, F. Y.
    Schwarz, T. F.
    Bosch, F. X.
    Harper, D. M.
    Hardt, K.
    Zahaf, T.
    Descamps, D.
    Struyf, F.
    Lehtinen, M.
    Dubin, G.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (01) : 106 - 116
  • [27] Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years
    Konno, Ryo
    Tamura, Shinobu
    Dobbelaere, Kurt
    Yoshikawa, Hiroyuki
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (05) : 847 - 855
  • [28] Bivalent AS04-adjuvanted HPV vaccine provides optimal cancer prevention for HPV types not included in the vaccine
    Beyer, Walter E. P.
    Osterhaus, Albert D. M. E.
    [J]. VACCINE, 2020, 38 (47) : 7414 - 7416
  • [29] Risk of Spontaneous Abortion in Young Women Exposed to Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in the United Kingdom: An Observational Cohort Study
    Baril, Laurence
    Rosillon, Dominique
    Willame, Corinne
    Angelo, Maria-Genalin
    Zima, Julia
    van den Bosch, Judith H.
    van Staa, Tjeerd
    Boggon, Rachel
    Bunge, Eveline
    Hernandez-Diaz, Sonia
    Chambers, Christina
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 491 - 491
  • [30] Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9-14 Years in the EU
    Lyseng-Williamson, Katherine A.
    [J]. PEDIATRIC DRUGS, 2014, 16 (03) : 247 - 253
12345